Even before the global pandemic forced healthcare to more rapidly adapt technology to let us continue practicing medicine while working to contain the spread of COVID-19, it was clear technology was becoming a more important part of the healthcare experience. That was made evident by the fact that large tech companies saw a tremendous opportunity in healthcare as Amazon, Alphabet, and Apple have all made various investments in this area over the past few years.
Now as telemedicine use has surged, digital pharmacies and delivery services are becoming more prominent, and clinical trials are using more wearables and remote-monitoring technology to safely collect data, the transition to more technology-infused healthcare is no longer a thing of the future. It is now. It is what healthcare will continue to be after COVID-19. And will we only see the addition of more technology and digital tools to healthcare in the future now that we have experienced the promise they can offer.
To get a better idea of what this future will look like and what technology we can expect, PM360 asked 10 experts:
How are life sciences marketers using new technology to offer patients a better healthcare experience or to better help and/or educate HCPs? Is there any specific technology you think offers marketers the most promise now and/or in the future?
How is the growing involvement of technology companies such as Amazon, Apple, Alphabet, etc., in healthcare impacting how life sciences companies must operate moving forward? What opportunities does this potentially open up for life sciences companies? What challenges will arise from their involvement? How will healthcare change as a result?
How can life sciences companies best assess the need, proper functionality, and potential success in the marketplace for different digital health solutions or digital therapeutics? Can you share any examples of solutions that have proven to be effective?
What areas of healthcare are being impacted the most by the advancement of technology? How will patients, HCPs, life sciences, or other healthcare stakeholders need to adjust as a result?